Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 11, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention

Derek Maetzold, CEO of Castle Biosciences, will participate in a panel discussion alongside other industry leaders during BIO 2025.
June 04, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®

Castle Biosciences' Founder and CEO Derek Maetzold Honored with Lifetime Achievement Award by The American Business Awards
May 29, 2025 16:30 ET | Source: Castle Biosciences, Inc.

New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes

Castle will present new data aimed at enhancing the clinical management of patients with cutaneous melanoma and uveal melanoma at ASCO 2025.
May 21, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference

Castle's executive management will present a company overview at the 2025 Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 7:35 am ET
May 09, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result

Castle presented new data from the first independent validation of the recently published COOG2.1 study by Harbour et al. at ARVO 2025.
May 07, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Castle Biosciences Celebrates Skin Cancer Awareness Month

Castle continues its ongoing patient advocacy partnerships and highlights cancer journey to drive education and awareness for Skin Cancer Awareness Month
May 05, 2025 16:06 ET | Source: Castle Biosciences, Inc.

Castle Biosciences Reports First Quarter 2025 Results

Castle Biosciences, Inc. (Nasdaq: CSTL) today announced its financial results for the first quarter ended March 31, 2025.
May 05, 2025 16:05 ET | Source: Castle Biosciences, Inc.

Castle Biosciences to Acquire Previse

Castle Biosciences, Inc. (Nasdaq: CSTL) has signed a definitive agreement to acquire Capsulomics, Inc., d/b/a Previse.
May 02, 2025 16:30 ET | Source: Castle Biosciences, Inc.

New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer

Castle Biosciences will share new data on its TissueCypher test for patients with Barrett’s esophagus at DDW 2025.
April 30, 2025 17:00 ET | Source: Castle Biosciences, Inc.

New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity

Castle announced the publication of a new study demonstrating DecisionDx-Melanoma outperforms AJCC staging and the CP-GEP test.